| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 | 10-Q |
| 27 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
8-K: Other Events
Immix Biopharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I |
| 29 Sep 2026 | FWP |
| 29 Sep 2026 | 424B5 |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Rel... |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | 10-Q |
| 20 Jul 2026 |
8-K: Other Events
As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Given his short tenure, management believes there is no material effect on the business. |
| 05 Jun 2026 | SCHEDULE 13G/A |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2026, at the 2026 Annual Meeting of stockholders (the “Annual Meeting”) of Immix Biopharma, Inc. (the “Company”), the Company’s stockholders voted on the following two (2) proposals and votes were cast as described below. Thes... |
| 29 May 2026 |
Form 4: Adams Helen C., Director
Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Ng Carey, Director
Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Marquet Magda, Director
Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Morris Gabriel S, Director
Granted 500,000 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Chang Nancy T, Director
Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Rachman Ilya M, Director
Granted 500,000 Stock Option (Right to Buy) |
| 29 May 2026 |
Form 4: Chudnovsky Yekaterina, Director
Received 6,250 shares as a grant or award · Granted 12,500 Stock Option (Right to Buy) |
Loading...